Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.
Journal Article (Journal Article)
Eight patients with disseminated Hodgkin's disease resistant to MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling. Two patients remain alive in unmaintained complete remission (CR) at 38 and 39 months after transplant. In the other six patients, reasons for failure included relapse of lymphoma (two patients), or death due to complications of the transplant procedure, including Legionnaire's disease, disseminated zoster, graft-v-host disease, and aspiration pneumonia secondary to severe mucositis. These results demonstrate that some patients with MOPP-resistant Hodgkin's disease can obtain prolonged CR following intensive chemoradiotherapy and allogeneic marrow transplantation.
Full Text
Duke Authors
Cited Authors
- Appelbaum, FR; Sullivan, KM; Thomas, ED; Buckner, CD; Clift, RA; Deeg, HJ; Neiman, PE; Sanders, JE; Stewart, P; Storb, R
Published Date
- November 1985
Published In
Volume / Issue
- 3 / 11
Start / End Page
- 1490 - 1494
PubMed ID
- 2414410
International Standard Serial Number (ISSN)
- 0732-183X
Digital Object Identifier (DOI)
- 10.1200/JCO.1985.3.11.1490
Language
- eng
Conference Location
- United States